HAVERTOWN, PA -- (Marketwired - Apr 3, 2014) - PeriRx LLC, a developer of non-invasive, oral diagnostic technology, recently announced that it will be introducing the world's most clinically advanced and scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma detection in the late spring.
According to PeriRx LLC's CEO Stephen M. Swanick, "This is a simple-to-use, painless and non-invasive test designed for front line healthcare practitioners that enables them to detect disease earlier, enhance patient wellness and reduce the overall cost of healthcare."
The salivary test is based on a strong scientific foundation of NIH-funded research with initial discovery and pre-validation work by Dr. David Wong of the University of California at Los Angeles. The test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.
These discriminatory salivary biomarkers have been clinically validated in multiple large trials including studies in collaboration with the National Cancer Institute and with premiere US academic medical centers such as the University of Michigan, Michigan State University and the Providence Health System in Detroit.